Related Experiment Videos
Gene-based strategies for the immunotherapy of cancer
T Tüting1, W J Storkus, M T Lotze
1Department of Surgery, University of Pittsburgh School of Medicine, PA 15261, USA.
Abstract:
T lymphocytes play a crucial role in the host's immune response to cancer. Although there is ample evidence for the presence of tumor-associated antigens on a variety of tumors, they are seemingly unable to elicit an adequate antitumor immune response. Modern cancer immunotherapies are therefore designed to induce or enhance T cell reactivity against tumor antigens. Vaccines consisting of tumor cells transduced with cytokine genes in order to enhance their immunogenicity have been intensely investigated in the past decade and are currently being tested in clinical trials. With the development of novel gene transfer technologies it has now become possible to transfer cytokine genes directly into tumors in vivo. The identification of genes encoding tumor-associated antigens and their peptide products which are recognized by cytotoxic T lymphocytes in the context of major histocompatibility complex class I molecules has allowed development of DNA-based vaccines against defined tumor antigens. Recombinant viral vectors expressing model tumor antigens have shown promising results in experimental models. This has led to clinical trials with replication-defective adenoviruses encoding melanoma-associated antigens for the treatment of patients with melanoma. An attractive alternative concept is the use of plasmid DNA, which can elicit both humoral and cellular immune responses following injection into muscle or skin. New insights into the molecular biology of antigen processing and presentation have revealed the importance of dendritic cells for the induction of primary antigen-specific T cell responses. Considerable clinical interest has arisen to employ dendritic cells as a vehicle to induce tumor antigen-specific immunity. Advances in culture techniques have allowed the generation of large numbers of immunostimulatory dendritic cells in vitro from precursor populations derived from blood or bone marrow. Experimental immunotherapies which now transfer genes encoding tumor-associated antigens or cytokines directly into professional antigen-presenting cells such as dendritic cells are under evaluation in pre-clinical studies at many centers. Gene therapy strategies, such as in vivo cytokine gene transfer directly into tumors as well as the introduction of genes encoding tumor-associated antigens into antigen-presenting cells hold considerable promise for the treatment of patients with cancer.
Insights
Cancer immunotherapies aim to boost T cell responses against tumors. Gene therapy strategies, including cytokine gene transfer and antigen-presenting cell modification, show promise for effective cancer treatment.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- T lymphocytes are critical for anti-tumor immunity.
- Tumor antigens often fail to elicit a sufficient immune response.
- Cancer immunotherapies seek to enhance T cell reactivity against tumors.
Purpose of the Study:
- To review modern cancer immunotherapies focusing on gene therapy approaches.
- To highlight advancements in T cell-mediated antitumor responses.
- To explore novel strategies for cancer treatment using gene transfer.
Main Methods:
- Investigated cytokine gene transduction in tumor cells for enhanced immunogenicity.
- Explored in vivo cytokine gene transfer directly into tumors.
- Developed DNA-based vaccines targeting tumor antigens recognized by cytotoxic T lymphocytes.
- Utilized recombinant viral vectors and plasmid DNA for antigen delivery.
- Examined the role of dendritic cells in antigen presentation and T cell induction.
- Studied gene transfer into antigen-presenting cells for tumor immunity.
Main Results:
- Cytokine-transduced tumor cell vaccines show promise in clinical trials.
- In vivo gene transfer technologies enable direct cytokine delivery to tumors.
- DNA vaccines and viral vectors have demonstrated efficacy in experimental models.
- Dendritic cell-based therapies are being developed to induce antigen-specific immunity.
- Gene therapy strategies targeting tumor antigens and cytokines hold significant therapeutic potential.
Conclusions:
- Gene therapy offers promising avenues for cancer treatment by enhancing immune responses.
- Direct in vivo gene transfer and dendritic cell modification represent key advancements.
- Future research and clinical applications are expected to leverage these gene therapy strategies for improved cancer outcomes.